PT  - JOURNAL ARTICLE
AU  - G. A. LePAGE
AU  - ABDUL KHALIQ
AU  - J. A. GOTTLIEB
TI  - STUDIES OF 9-β-D-ARABINOFURANOSYLADENINE IN MAN
DP  - 1973 Nov 01
TA  - Drug Metabolism and Disposition
PG  - 756--759
VI  - 1
IP  - 6
4099  - http://dmd.aspetjournals.org/content/1/6/756.short
4100  - http://dmd.aspetjournals.org/content/1/6/756.full
SO  - Drug Metab Dispos1973 Nov 01; 1
AB  - 9-β-D-Arabinofuranosyladenine was given to two patients by relatively rapid (½, 2 hr) intravenous infusion, to two patients as a continuous intravenous drip over 24 hr, and to two patients as an intramuscular suspension. Blood plasma levels and urinary excretion of ara-A1 and the chief metabolic product. 9-β-D-arabinofuranosylhypoxanthine, were measured at intervals up to 24 hr. Rapid intravenous infusions resulted in 88 and 97% recoveries in urine by 24 hr, as ara-H and ara-A. Urinary excretion after administration as a continuous intravenous drip was 33 and 41%, respectively, in the first 24 hr. The two patients receiving intramuscular injection excreted only 1.7 and 7.1% of the dose, respectively, in 24 hr. The latter finding would indicate poor absorption of an intramuscular dose. Copyright © 1973 by The American Society for Pharmacology and Experimental Therapeutics